HomeCompareBDVSY vs ABBV

BDVSY vs ABBV: Dividend Comparison 2026

BDVSY yields 3.24% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $76.6K in total portfolio value
10 years
BDVSY
BDVSY
● Live price
3.24%
Share price
$27.06
Annual div
$0.88
5Y div CAGR
3.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.7K
Annual income
$589.34
Full BDVSY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BDVSY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDVSYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDVSY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDVSY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDVSY
Annual income on $10K today (after 15% tax)
$275.18/yr
After 10yr DRIP, annual income (after tax)
$500.94/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,555.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDVSY + ABBV for your $10,000?

BDVSY: 50%ABBV: 50%
100% ABBV50/50100% BDVSY
Portfolio after 10yr
$64.0K
Annual income
$12,680.55/yr
Blended yield
19.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BDVSY
No analyst data
Altman Z
3.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDVSY buys
0
ABBV buys
0
No recent congressional trades found for BDVSY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDVSYABBV
Forward yield3.24%3.06%
Annual dividend / share$0.88$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.6%40.6%
Portfolio after 10y$25.7K$102.3K
Annual income after 10y$589.34$24,771.77
Total dividends collected$4.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BDVSY vs ABBV ($10,000, DRIP)

YearBDVSY PortfolioBDVSY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,035$335.39$11,550$430.00$515.00ABBV
2$12,166$358.36$13,472$627.96$1.3KABBV
3$13,400$382.53$15,906$926.08$2.5KABBV
4$14,746$407.94$19,071$1,382.55$4.3KABBV
5$16,213$434.66$23,302$2,095.81$7.1KABBV
6$17,811$462.71$29,150$3,237.93$11.3KABBV
7$19,550$492.15$37,536$5,121.41$18.0KABBV
8$21,441$523.03$50,079$8,338.38$28.6KABBV
9$23,498$555.41$69,753$14,065.80$46.3KABBV
10$25,732$589.34$102,337$24,771.77$76.6KABBV

BDVSY vs ABBV: Complete Analysis 2026

BDVSYStock

The Bidvest Group Limited operates in trading, services, and distribution businesses in South Africa and internationally. The company operates through Services, Branded Products, Freight, Automotive, Commercial Products, Financial Services, and Properties segments. It is involved in the online motor retailing and vehicle auctioneering activities; provision of road assistance, vehicle towing, tyre replacement/change, fuel top up, locksmith, and legal advice services; and manufacturing, distribution, and trading of consumer and industrial day-to-day branded products. The company also distributes electrical, cable and allied products, solutions, and services to wholesale, industrial, mining, contractor, construction, engineering, and retail sectors; and provides a range of banking, insurance, foreign exchange, fleet management, asset management, trade finance, financial emigration, wealth externalization, and other financial services for the corporate, business, and individual markets. In addition, it offers freight management services; terminal operations and support, international clearing and freight forwarding, integrated logistics, supply chain solutions, and marine and insurance services; a suite of services relating to office products, office automation, and office furniture; outsourced customer communication services; facilities management, security, travel, aviation, and allied services; and commercial, industrial, financial, automotive, freight, and logistics services, as well as supplies stationery, paper or printer cartridges, and packaging and data services. Further, the company manufactures, markets, and distributes healthcare products; develops, owns, and manages various properties; and provides professional property services, as well as engages in the food and distribution business. The Bidvest Group Limited was founded in 1988 and is headquartered in Johannesburg, South Africa.

Full BDVSY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BDVSY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDVSY vs SCHDBDVSY vs JEPIBDVSY vs OBDVSY vs KOBDVSY vs MAINBDVSY vs JNJBDVSY vs MRKBDVSY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.